Losartan (Cozaar) is generally used to manage symptoms that create noticeable physiological strain over the long term, supporting chronic health conditions. This medication is commonly used across key therapeutic domains to offer supportive and stabilizing effects. Its application is relevant for easing the impact of essential hypertension, and may assist with lowering the chance of certain cardiovascular events in patients with hypertension and Left Ventricular Hypertrophy (LVH), and contributes to supporting kidney health in cases of diabetic nephropathy.

The medication is commonly used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden. It is applied in settings marked by temporary physiological imbalance and is relevant when additional symptomatic support is appropriate for managing long-term conditions. This support may assist with maintaining functional stability and general well-being.

Quick Fact: Relief for Sustained Vascular Strain
Losartan assists with managing groups of symptoms that may become intense or disruptive, specifically supports the management of elevated arterial pressure and the subsequent strain on the heart and kidneys.

Regulatory References

1. NIH DailyMed Label for LOSARTAN POTASSIUM

Official Regulatory Eligibility for Cozaar 100 mg (Losartan)

The use of Cozaar is defined by strict regulatory population constraints. Contraindicated populations who must not use the medicine include pregnant women (discontinue immediately if pregnancy is detected), patients with known hypersensitivity to losartan, and patients with diabetes mellitus who are concurrently taking aliskiren.

Category	Eligibility Rule
Allowed Populations	Adults and pediatric patients ge 6 years of age with hypertension; adults with Type 2 Diabetes and nephropathy.
Not Recommended	Children under 6 years of age or pediatric patients with severe renal impairment (eGFR <30 mL/min/1.73 m^2).
Use Not Established	Patients with severe hepatic impairment.

Eligibility is also conditional for patients who are volume- or salt-depleted, requiring the depletion to be corrected prior to administration. During lactation, official labeling requires a choice between discontinuing the medicine or discontinuing breastfeeding.

---

Eligibility Classifications (High-Level)

• Eligibility Severity: Contraindicated; Not Recommended; Conditional Use; Established Profile.

Connection to the overall eligibility profile: Regulatory documents define use by establishing mandatory contraindications and issuing restrictions based on age, reproductive status, and organ function. These official statements delineate the population limits, requiring certain physiological conditions to be addressed or specific comorbid states to be absent before the drug can be administered.

Interactions with other medicines and products

The official interaction profile for Losartan potassium is defined by documented pharmacodynamic and pharmacokinetic outcomes that necessitate specific co-administration constraints, as detailed in regulatory documents.

Interaction-Related Restrictions

A key restriction is the contraindication of co-administering Losartan potassium with Aliskiren in patients with diabetes due to the officially documented risk of renal impairment, hyperkalemia, and hypotension. Dual inhibition of the Renin-Angiotensin System (RAS), such as combining Losartan with an ACE inhibitor, is discouraged for similar reasons.

Pharmacodynamic Interactions

Co-administration with agents that increase serum potassium (including potassium-sparing diuretics, potassium supplements, and salt substitutes containing potassium) carries a documented risk of hyperkalemia. Furthermore, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can reduce Losartan's antihypertensive effect and increase the risk of renal impairment. Co-administration with Lithium is documented to increase serum Lithium concentrations.

Exposure Modification

Specific medicinal products are documented to alter Losartan's systemic exposure (AUC) via metabolic pathways. For example, the CYP2C9 inhibitor Fluconazole causes a documented increase in Losartan exposure, while Phenobarbital leads to a documented reduction in exposure for both Losartan and its active metabolite. This clearance alteration is also noted in specific populations, with patients having hepatic impairment documented to have approximately five times higher Losartan plasma concentrations than healthy subjects.

Cozaar (losartan potassium) acts as a selective and competitive antagonist at the Angiotensin II type 1 ( AT1) receptor. Losartan is a prodrug, and approximately 14% of the administered dose is converted via hepatic cytochrome P450 enzymes ( CYP2C9 and CYP3A4) to its principal active metabolite, EXP3174. This metabolite is a non-competitive antagonist and exhibits a substantially greater binding affinity for the AT1 receptor than the parent compound.

The biological target, the AT1 receptor, is a G protein-coupled receptor ( G q protein-coupled) found in numerous tissues, including vascular smooth muscle and the adrenal gland. Angiotensin II normally binds to this receptor, initiating an intracellular cascade involving the activation of phospholipase C, which generates diacylglycerol (DAG) and inositol triphosphate ( IP3). This leads to the release of intracellular Ca^2+ stores. By blocking the binding of Angiotensin II to the AT1 receptor, losartan and EXP3174 prevent the Angiotensin II-mediated intracellular signaling. The downstream effect is the inhibition of vascular smooth muscle contraction and the suppression of Angiotensin II-induced aldosterone secretion by the adrenal cortex. The system-level physiological consequence of this blockade is a reduction in total peripheral vascular resistance and, secondarily, an increase in urinary sodium and water excretion.

How to Use Cozaar 100 mg

Losartan potassium (Cozaar) is provided as a film-coated tablet intended solely for oral administration. The official usage pattern establishes a standardized, long-term maintenance protocol for chronic conditions. The tablet can be administered with or without food, offering flexibility in its once-daily schedule.

Dosing Patterns and Maximum Use

For most adult indications, the typical initial dose is 50 mg once daily. Based on the individual's response, the dosage may be adjusted upward. The total daily dosage must not exceed 100 mg, which is the maximum dose for the 100 mg strength tablet.

Population-Specific Instructions

The usage protocol includes specific starting dose adjustments for certain physiological states. Patients with evidence of mild-to-moderate liver impairment or those with intravascular volume depletion (e.g., from high-dose diuretic therapy) should begin treatment with a lower starting dose of 25 mg once daily.

For pediatric patients (ages 6 years and older), the starting dose is based on weight at 0.7 mg/kg once daily, with a maximum limit of 50 mg per day. For children who cannot swallow tablets, an oral suspension must be prepared by a pharmacist.

Handling Missed Administration

If a dose is missed, the user should take the next dose at the regularly scheduled time. It is procedurally specified that a double dose must not be taken to compensate for a missed dose.

Research evidence / Overview of studies for Cozaar 100 mg

Evidence for use in Essential Hypertension

Losartan (Cozaar) in the context of high blood pressure research examined how treatment was associated with systemic pressure measurements. Research consists primarily of controlled clinical studies, including short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies primarily research examined changes in systolic and diastolic blood pressure, which are key outcomes monitoring physiological strain.

Findings describe patterns observed in the studies where Losartan treatment was associated with the measured outcome of blood pressure change when compared to starting levels. Multiple dose-response studies were evaluated in various patient groups, and these trials reported that the very lowest doses studied did not demonstrate consistent antihypertensive measurements in the observed populations.

Evidence for use in Reducing Cardiovascular Risk with LVH

Losartan was studied for its association with certain risks in patients with high blood pressure who also have Left Ventricular Hypertrophy (LVH). The evidence is derived from one large-scale, long-term active-controlled clinical outcome trial (the LIFE Study), which was evaluated in patients aged 55 years and older.

Researchers examined a single, combined outcomes related to systemic or functional imbalance, including cardiovascular death, stroke, or heart attack. Analysis of the individual endpoints reported a specific observation: in the Losartan-treated group, the incidence of total strokes was numerically lower compared to the active comparator group. The official regulatory documentation explicitly notes that the finding related to the incidence of stroke events did not apply to the subgroup analysis of Black patients in the pivotal trial.

Evidence for use in Diabetic Nephropathy

The research foundation is a large-scale, long-term, placebo-controlled trial (the RENAAL Study), which was evaluated in patients with Type 2 diabetes who also had hypertension and signs of kidney impairment. Researchers monitored the time until patients reached a composite renal endpoint, including the need for dialysis or transplant, or death.

Studies reported patterns in the time until patients reached this endpoint in the Losartan group compared to the control group. Additionally, the research highlights changes measured during the study period related to measurements of urinary protein excretion reported were different in the Losartan group. However, the study’s final data reported no discernible difference in all-cause mortality compared to the control group.

Key Studies & References

1. LOSARTAN POTASSIUM TABLETS, 100 MG - Official Drug Label Summary (DailyMed)
2. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Common questions about Cozaar 100 mg (FAQ)

---

Q: Does Cozaar cause sleep disturbances or insomnia?

Official product information indicates that insomnia (difficulty sleeping) has been reported as a common side effect in clinical trials. Experiencing changes in sleep patterns is consistent with this reported event.

---

Q: Is dizziness or lightheadedness a common experience when starting Cozaar?

Dizziness is described in official documents as the most commonly reported adverse reaction in clinical trials for patients taking Losartan for high blood pressure. This is considered a frequent and reported experience.

---

Q: Does taking Cozaar lead to a persistent dry cough?

Official data confirms cough is a reported side effect, with an incidence of 1% to 10% in clinical trials.

---

Q: Is stuffy nose (nasal congestion) reported as a side effect of this medicine?

Yes, official product information lists nasal congestion and upper respiratory infection as common side effects associated with the use of Losartan. This is a recognized adverse reaction.

---

Q: Can Cozaar cause back pain or muscle/joint discomfort?

Official data lists back pain and myalgia (muscle pain) as common side effects. Arthralgia (joint pain) is also reported, though at an undocumented frequency. These events are reported in official data.

---

Q: Does Cozaar cause low blood sugar (hypoglycemia) in diabetic patients?

Hypoglycemia (low blood sugar) is listed as a common reported side effect in patients with Type 2 diabetes who are taking Losartan for diabetic kidney disease (nephropathy). This event is listed as a common reported side effect in this specific patient population.

---

Q: Can Cozaar cause memory issues or mental fogginess?

The official label lists general nervous system effects such as dizziness and somnolence (drowsiness). Memory impairment is also reported as a nervous system event, though the frequency is not quantified in the main summary.

---

Q: Is Cozaar 100 mg also used to protect the kidneys in patients with certain conditions?

Regulatory indications state that Cozaar is used to slow the progression of kidney disease (nephropathy) in patients who have Type 2 diabetes and high blood pressure. This is an established therapeutic purpose beyond managing blood pressure alone.

---

Q: How does Cozaar help lower the risk of stroke in certain people with high blood pressure?

Cozaar is specifically indicated to reduce the risk of stroke in patients with hypertension and Left Ventricular Hypertrophy (LVH), a condition where the heart muscle is thickened. This benefit was observed and documented in major clinical trials.

---

Q: How quickly does Cozaar start to lower blood pressure after the first dose?

Losartan is a medicine that is rapidly absorbed after being taken orally. Official data confirms the medicine reaches its peak plasma concentration in the blood within 1 to 2 hours of administration. Its presence in the body, which enables action, is established during this time frame.

---

Q: Does Cozaar treat high blood pressure, or is it only used to manage the condition?

Cozaar is indicated for the treatment and long-term management of high blood pressure. While it is a chronic treatment that helps control the condition, it is not described as a cure.

---

Q: What happens if someone stops taking Cozaar suddenly?

Abrupt discontinuation of any antihypertensive medicine can potentially lead to a rapid increase in blood pressure. Regulatory guidance advises against abrupt discontinuation of any antihypertensive medicine.

---

Q: What are the common reasons a doctor might choose an ARB like Cozaar instead of an ACE inhibitor like lisinopril?

Cozaar belongs to a different class of medicine (ARBs) than ACE inhibitors. A key difference noted in regulatory documentation is that Losartan is from a class of medicines not typically associated with the cough reported with ACE inhibitors.

---

Q: Is it true that Cozaar may be less effective for people of African-American descent?

Official reports on the pivotal stroke-risk reduction study (the LIFE study) noted that the finding on stroke risk reduction did not apply to the subgroup analysis of Black patients in that trial. This is a specific observation from the research evidence.

---

Q: Does Cozaar interact with NSAID pain relievers like ibuprofen or naproxen?

Yes, official warnings state that co-administration with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) can have two documented effects. It may reduce the blood pressure-lowering effect of Cozaar, and it may also increase the risk of renal impairment (kidney damage). This is a known interaction.

---

Q: Does Cozaar interact with salt substitutes that contain potassium?

Regulatory documents indicate that taking Cozaar alongside salt substitutes containing potassium may increase the risk of hyperkalemia (high blood potassium). This is a known interaction.

--TEMPORARY BREAK--

Q: Can taking Cozaar affect the level of lithium in the blood?

Yes, official drug interaction warnings confirm that co-administration with the medicine Lithium is documented to increase serum Lithium concentrations in the blood. This requires careful consideration.

---

Q: What are the known risks for people with liver problems taking Cozaar?

Official information states that a lower starting dose is required for patients with mild-to-moderate liver impairment. Rare instances of acute liver injury have been reported, and patients with liver problems may have higher concentrations of the drug in their plasma.

---

Q: Does Cozaar have a known risk for people with pre-existing kidney problems?

Official warnings state that Cozaar may cause worsening of renal function and acute renal failure (sudden kidney damage). This risk is particularly noted in susceptible patients, such as those with renal artery stenosis.

---

Q: Are regular blood and urine tests necessary when taking Cozaar?

Official safety information states that periodic monitoring of serum potassium and renal function is necessary. This monitoring is required, especially for those with existing kidney impairment.

---

Q: What official warnings exist about taking Cozaar during pregnancy?

Cozaar carries a Boxed Warning indicating a significant risk to the developing baby. Regulatory documents state the medicine must be discontinued as soon as pregnancy is detected due to the risk of injury and death to the fetus.

---

Q: Can Cozaar be taken if a patient is breastfeeding?

Official product information advises that a choice must be made between discontinuing the drug or discontinuing breastfeeding.

---

Q: Is Cozaar 100 mg appropriate for use in children?

Official information indicates the drug is designated for use in pediatric patients aged 6 years and older for hypertension. It is not designated for use in younger children.

---

Q: Can Cozaar affect fertility?

Official sources state there is no available evidence to suggest that taking Losartan reduces fertility in either men or women.

---

Q: How should Cozaar 100 mg tablets be disposed of?

Unused or expired medication should be discarded according to the local regulations or the general governmental guidelines for household pharmaceutical waste in your area. Tablets should not be flushed down the toilet.

How to Store and Dispose of Cozaar 100 mg

Cozaar (losartan potassium) 100 mg tablets must be stored at Controlled Room Temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in the original container to ensure it is protected from light and moisture and to maintain its stability until the expiration date. The container should be kept tightly closed.

All tablets must be stored strictly out of the sight and reach of children.

For disposal, if no specific instructions are provided on the label, the tablets should not be flushed down a toilet or disposed of in wastewater. Unused or expired medication should be discarded according to local regulations or general governmental guidelines for household pharmaceutical waste.